Esuprone

CAS No. 91406-11-0

Esuprone( —— )

Catalog No. M34246 CAS No. 91406-11-0

Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 193 In Stock
5MG 205 In Stock
10MG 302 In Stock
25MG 489 In Stock
50MG 695 In Stock
100MG 977 In Stock
200MG 1321 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Esuprone
  • Note
    Research use only, not for human use.
  • Brief Description
    Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.
  • Description
    Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    MAO
  • Recptor
    MAO
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    91406-11-0
  • Formula Weight
    282.31
  • Molecular Formula
    C13H14O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1C=2C(=CC(OS(CC)(=O)=O)=CC2)OC(=O)C1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AnnH31

    AnnH31 is a potent Dyrk1A inhibitor with an IC50 value of 81 nM.AnnH31 inhibits MAO-A with an IC50 of 3.2 μM.AnnH31 can be used as a probe to confirm the involvement of DYRK1A in cellular phosphorylation.

  • PSB-1491

    PSB-1491 is a selective and competitive monoamine oxidase B inhibitor with IC50 of 0.386 nM, >25000-fold selective versus MAO-A.

  • AChE/BChE/MAO-B-IN-1

    AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively.